Nanobiotix Shares Climb Over 3%, Leading Gains in the SBF 120
In mid-morning trading, the French biotech company moves forward, ranking among the top performers in the SBF 120. The stock continues its recovery that began earlier in the week, following a period of consolidation after reaching a record high in mid-May. The rebound occurs as the Parisian market also trends upward.
A Rebound of More Than 3% Bringing the Stock Closer to its Short-Term Moving Averages
Nanobiotix shares are up 3.13% at €31.64 in mid-morning trading, compared to a previous close of €30.68. The stock is among the top gainers in the SBF 120, while the broader index is up 0.31%. Over the week, the stock has regained nearly 12%, mitigating part of the 27.8% monthly decline following its mid-May record high.
The price remains slightly below its 20-day moving average (MM20) at €32.07 (a gap of -1.34%) and its 50-day moving average (MM50) at €32.14 (-1.56%), two thresholds that represent immediate technical challenges. The long-term outlook remains very favorable: the 200-day moving average (MM200) at €22.51 is more than 40% below the current price, reflecting the magnitude of the annual rally (+679%). The RSI at 46 indicates a neutral setup, consistent with a stabilization phase after the recent declines.
Clinical Pipeline and Enhanced Cash Reserves Structure Upcoming Milestones
Beyond daily trading movements, the biotech's profile is supported by preliminary Phase 2 data released in early June on JNJ-1900 (NBTXR3) for inoperable lung cancer, with a response observed in 6 of the 7 patients treated. On June 2, 2026, during the first quarter earnings release, the company also reported a net cash position of €42.1 million as of March 31, following a capital increase of €86.1 million through pre-financed warrants. Opportunities identified by the company at that time include strengthening the Nanoprimer platform, while limited progress in the current standard of care for inoperable NSCLC and the study's analysis protocol were cited as risks.
On June 2, Nanobiotix also joined the Euronext Tech Leaders segment, aimed at enhancing visibility among international investors. In the short term, reclaiming the moving averages at €32.07 and €32.14 is the technical threshold to watch to confirm the stabilization that began since the monthly low.
